Repetitive Transcranial Magnetic Stimulation in ADHD

Although there are very effective treatment approaches for ADHD available, the clinical management has its limits and a search for new treatment modalities is useful. rTMS found its use in neurology and is widely applied in psychiatric research and although its effect seems mild, it can be specific to some extend. The text reviews current knowledge on the neurobiology of ADHD symptoms with regard to a possible rTMS treatment. The basics of the rTMS method are described. The use of rTMS is summarized both generally in psychiatric disorders and specifically in ADHD. The safety issues are discussed both in adults and children. The text also brings a case study where rTMS was applied in an adult patient with ADHD

Transcranial Magnetic Stimulation in Schizophrenia

Transcranial magnetic stimulation (TMS) is a method that can be used in neurophysiological research of schizophrenia and in the treatment of some symptoms or syndromes of this mental disorder. The most important indications for TMS (or repetitive TMS—rTMS) are the negative symptoms of schizophrenia and auditory hallucinations. Other less proven indications include cognitive deficit, especially working memory. This text summarizes general knowledge about (r)TMS and its use in schizophrenia. According to recent experiences, TMS is a very promising experimental and therapeutic method, but it needs further research for its optimized use

Block of flats Velká Bíteš

V diplomové práci vypracovávám projektovou dokumentaci k objektu pro bydlení, který bude sloužit pro 88 osob. Objekt je nepodsklepený s pěti nadzemními podlažími a osmi vestavěnými garážemi. Obvodové nosné konstrukce jsou ze systému Porotherm, objekt je zastřešen plochou střechou.In the masters´s thesis I make the layout documents of a building for living which will be used for 88 persons. The building is cellarless with five overhead floors and eight inbuilt garages. Peripheral structural framings are made of Porotherm blocks. The whole building is covered with flat roof.

Transcranial Magnetic Stimulation in Neuropsychiatry

This book describes several aspects of transcranial magnetic stimulation (TMS) in neuropsychiatry: inhibitory and excitatory mechanisms of the human brain, the use of TMS in the research and treatment of cognitive disorders, various aspects of TMS application aimed at the cerebellum, its effects on impulsivity in attention deficit hyperactivity disorder and borderline personality disorder, its effects in the treatment of tinnitus and obsessive-compulsive disorder, pain and chronic headache, and finally the safety of TMS for staff. Hopefully this book will help to expand the knowledge of TMS

Selected neuroendocrine factors as potential molecular biomarkers of early non-affective psychosis course in relation to treatment outcome: A pilot study

The aim of this pilot study was to find whether the dysregulation of neuroendocrine biomarker signaling pathways in the first episode of non-affective psychosis is a predictive factor of treatment outcome. Patients with the first episode of non-affective psychosis (N = 29) were examined at admission, at discharge, and at follow-up (N = 23). The biomarkers included serum aldosterone, cortisol, free thyroxine, thyroid stimulating hormone, and prolactin. We revealed lower baseline aldosterone and higher baseline cortisol concentrations in patients with very good outcome compared to those with good outcome after one year. We failed to reveal any significant association between treatment outcome and neurohumoral biomarkers in the whole sample at 1-year follow-up. However, baseline aldosterone concentrations negatively correlated with total PANSS scores at the discharge. Lower baseline aldosterone and higher baseline cortisol concentrations have the potential to predict a more favorable outcome for patients with the first episode of psychosis

Depression and Anxiety after Acute Myocardial Infarction Treated by Primary PCI.

AIMS:The main objective of the study was to find out prevalence of depression and anxiety symptoms in the population of patients with AMI with ST-segment elevation (STEMI), treated with primary PCI (pPCI). Secondary target indicators included the incidence of sleep disorders and loss of interest in sex. METHODS AND RESULTS:The project enrolled 79 consecutive patients with the first AMI, aged <80 years (median 61 years, 21.5% of women) with a follow-up period of 12 months. Symptoms of depression or anxiety were measured using the Beck Depression Inventory II tests (BDI-II, cut-off value ≥14) and Self-Rating Anxiety Scale (SAS, cut-off ≥ 45) within 24 hours of pPCI, before the discharge, and in 3, 6 and 12 months). Results with the value p<0.05 were considered as statistically significant. The BDI-II positivity was highest within 24 hours after pPCI (21.5%) with a significant decline prior to the discharge (9.2%), but with a gradual increase in 3, 6 and 12 months (10.4%; 15.4%; 13.8% respectively). The incidence of anxiety showed a relatively similar trend: 8.9% after pPCI, and 4.5%, 10.8% and 6.2% in further follow-up. CONCLUSIONS:Patients with STEMI treated by primary PCI have relatively low overall prevalence of symptoms of depression and anxiety. A significant decrease in mental stress was observed before discharge from the hospital, but in a period of one year after pPCI, prevalence of both symptoms was gradually increasing, which should be given medical attention